CLINICAL TRIALS PROFILE FOR FIBRICOR
✉ Email this page to a colleague
All Clinical Trials for FIBRICOR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00961116 ↗ | Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate) | Completed | Mutual Pharmaceutical Company, Inc. | Phase 1 | 2007-10-01 | This study will evaluate the bioequivalence of 105 mg fenofibric acid tablets relative to 145 mg fenofibrate tablets in healthy volunteers under fasting conditions. A secondary objective is to characterize the pharmacokinetic profile of fenofibric acid when administered as a single 105 mg dose to healthy volunteers in a fasted state. Safety and tolerability of this regimen will also be evaluated. |
| NCT01472380 ↗ | A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz | Completed | Mutual Pharmaceutical Company, Inc. | Phase 1 | 2011-11-01 | Efavirenz is predominantly metabolized by cytochrome P450 (CYP) 2B6. Fenofibric Acid is an inhibitor of CYP2B6. This study will evaluate the effect of multiple doses of fenofibric acid at steady-state on the pharmacokinetics of single-dose efavirenz in healthy adult subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FIBRICOR
Condition Name
Clinical Trial Locations for FIBRICOR
Trials by Country
Clinical Trial Progress for FIBRICOR
Clinical Trial Phase
Clinical Trial Sponsors for FIBRICOR
Sponsor Name
